{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:34:28Z","timestamp":1795149268080,"version":"4.10.3"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"22","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["147KL-Q3"],"award-info":[{"award-number":["147KL-Q3"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["24-0087"],"award-info":[{"award-number":["24-0087"]}],"id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015643\/1"],"award-info":[{"award-number":["MR\/R015643\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/T008709\/1"],"award-info":[{"award-number":["BB\/T008709\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7893\/A29290"],"award-info":[{"award-number":["C7893\/A29290"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding Fc\u03b3R expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune-engaging antibody design and patient stratification. In this study, we investigated FcR-expressing immune effector cells in HER2+ and triple-negative breast cancers (TNBC), including neoadjuvant chemotherapy\u2013resistant disease. Fc\u03b3RIIIa expression, Fc\u03b3RIIIa+ NK cells, and classically activated (M1-like) macrophages correlated with improved anti-HER2 antibody efficacy. Fc\u03b3RIIIa protein and Fc\u03b3RIIIa+ NK cells and macrophages were present in primary TNBC and retained in treatment-resistant tumors. Fc\u03b3RIIIa was spatially associated with folate receptor alpha\u2013positive (FR\u03b1+) tumor areas at baseline and in residual tumors following neoadjuvant chemotherapy. Wild-type and Fc-engineered antibodies recognizing two breast cancer\u2013associated antigens, HER2 and the emerging TNBC target FR\u03b1, were designed and generated to have increased Fc\u03b3RIIIa-expressing effector cell engagement. The combination of glycoengineering, including fucose removal from the N-linked Fc glycan, and Fc point mutations greatly increased antibody affinity for and retention on Fc\u03b3RIIIa. The Fc-engineered antibodies enhanced immune effector activity against HER2+ breast cancer and TNBC, altering proinflammatory cytokine production by NK cells and tumor-conditioned macrophages and skewing macrophages toward proinflammatory states. Furthermore, the Fc-engineered antibodies restricted orthotopic HER2+ and FR\u03b1+ breast cancer xenograft growth at doses suboptimal for equivalent wild-type antibodies and recruited Fc\u03b3RIIIa-expressing cells into tumors. Antibody design through combined glycoengineering and Fc point mutations to enhance Fc\u03b3RIIIa engagement of tumor-infiltrating effector cells may be a promising strategy for developing therapies for patients with aggressive and treatment-resistant breast cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Assessment of Fc receptors and immune cells in breast cancer enables development of tailored engineering strategies for tumor-targeting monoclonal antibodies with enhanced immune-stimulating and anticancer attributes by combining glycoengineering and Fc mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-3174","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:01:16Z","timestamp":1761228076000},"page":"4521-4540","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-9268","authenticated-orcid":false,"given":"Alicia M.","family":"Chenoweth","sequence":"first","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2988-2786","authenticated-orcid":false,"given":"Anthony","family":"Cheung","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3968-9234","authenticated-orcid":false,"given":"Jitesh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-9048","authenticated-orcid":false,"given":"Rebecca","family":"Adams","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-1973","authenticated-orcid":false,"given":"Gabriel","family":"Osborn","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7889-7164","authenticated-orcid":false,"given":"Katie","family":"Stoker","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."},{"name":"3Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-8298","authenticated-orcid":false,"given":"Melanie","family":"Grandits","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0118-4548","authenticated-orcid":false,"given":"Roman","family":"Laddach","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."},{"name":"3Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-0352","authenticated-orcid":false,"given":"Jennifer","family":"Trendell","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9383-9669","authenticated-orcid":false,"given":"Blanca","family":"Navarro-Llinas","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2379-515X","authenticated-orcid":false,"given":"Erin","family":"Suriawinata","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1212-5498","authenticated-orcid":false,"given":"Amanda","family":"Gross","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4539-1290","authenticated-orcid":false,"given":"Amanda","family":"Clarke","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3554-024X","authenticated-orcid":false,"given":"Lev","family":"Brown","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7671-1143","authenticated-orcid":false,"given":"Judit","family":"Cserny","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-865X","authenticated-orcid":false,"given":"Lenny","family":"Moise","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-6583","authenticated-orcid":false,"given":"Shashi","family":"Jatiani","sequence":"additional","affiliation":[{"name":"4SeromYx Systems, Inc., Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2412-4389","authenticated-orcid":false,"given":"Alexandra","family":"McCraw","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4589-9697","authenticated-orcid":false,"given":"Benjamina","family":"Esapa","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6685-5480","authenticated-orcid":false,"given":"Syed","family":"Haider","sequence":"additional","affiliation":[{"name":"5The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3071-3776","authenticated-orcid":false,"given":"Jelmar","family":"Quist","sequence":"additional","affiliation":[{"name":"6Cancer Bioinformatics, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-3793","authenticated-orcid":false,"given":"Kristina M.","family":"Ilieva","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1498-1594","authenticated-orcid":false,"given":"Anna M.","family":"Davies","sequence":"additional","affiliation":[{"name":"7Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-3308","authenticated-orcid":false,"given":"Pablo","family":"Romero-Clavijo","sequence":"additional","affiliation":[{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-4127","authenticated-orcid":false,"given":"Thomas","family":"S\u00e9nard","sequence":"additional","affiliation":[{"name":"8Ludger, Ltd., Abingdon, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1112-217X","authenticated-orcid":false,"given":"Jack","family":"Cheeseman","sequence":"additional","affiliation":[{"name":"8Ludger, Ltd., Abingdon, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-7544","authenticated-orcid":false,"given":"Richard A.","family":"Gardner","sequence":"additional","affiliation":[{"name":"8Ludger, Ltd., Abingdon, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-0890","authenticated-orcid":false,"given":"Daniel I.R.","family":"Spencer","sequence":"additional","affiliation":[{"name":"8Ludger, Ltd., Abingdon, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8403-1282","authenticated-orcid":false,"given":"Sophia","family":"Tsoka","sequence":"additional","affiliation":[{"name":"3Department of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-7162","authenticated-orcid":false,"given":"Sheeba","family":"Irshad","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"9School of Cancer and Pharmaceutical Sciences, King\u2019s College London, Comprehensive Cancer Centre, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-2980","authenticated-orcid":false,"given":"James M.","family":"McDonnell","sequence":"additional","affiliation":[{"name":"7Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, King\u2019s College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-201X","authenticated-orcid":false,"given":"Anita","family":"Grigoriadis","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"6Cancer Bioinformatics, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-2901","authenticated-orcid":false,"given":"Andrew N.J.","family":"Tutt","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"5The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-7810","authenticated-orcid":false,"given":"Sophia N.","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"1Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King\u2019s College London, Guy\u2019s Cancer Centre, London, United Kingdom."},{"name":"2St. John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King\u2019s College London, Guy\u2019s Hospital, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2025111403144648100_bib1","first-page":"451","article-title":"Global cancer statistics 2022: the trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem Biol Lett"},{"key":"2025111403144648100_bib2","doi-asserted-by":"crossref","first-page":"e14384","DOI":"10.1111\/cbdd.14384","article-title":"Breast cancer and its therapeutic targets: a comprehensive review","volume":"103","author":"Singh","year":"2023","journal-title":"Chem Biol Drug Des"},{"key":"2025111403144648100_bib3","doi-asserted-by":"crossref","first-page":"1006429","DOI":"10.3389\/fonc.2022.1006429","article-title":"Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2025111403144648100_bib4","doi-asserted-by":"crossref","first-page":"1244781","DOI":"10.3389\/fonc.2023.1244781","article-title":"Triple-negative breast cancer: from none to multiple therapeutic targets in two decades","volume":"13","author":"Carvalho","year":"2023","journal-title":"Front Oncol"},{"key":"2025111403144648100_bib5","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","article-title":"Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer","volume":"24","author":"Cheung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025111403144648100_bib6","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","article-title":"Tumor-infiltrating B lymphocyte profiling identifies IgG-Biased, clonally expanded prognostic phenotypes in triple-negative breast cancer","volume":"81","author":"Harris","year":"2021","journal-title":"Cancer Res"},{"key":"2025111403144648100_bib7","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-22-0543","article-title":"Dynamic changes in the NK-Neutrophil-and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy-resistant early breast cancers","volume":"28","author":"Gazinska","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025111403144648100_bib8","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.3390\/cancers15225493","article-title":"The role of the tumor microenvironment in triple-positive breast cancer progression and therapeutic resistance","volume":"15","author":"Pu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025111403144648100_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","article-title":"Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era","volume":"60","author":"Mand\u00f3","year":"2021","journal-title":"Breast"},{"key":"2025111403144648100_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"2025111403144648100_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imcb.12326","article-title":"Harnessing the immune system via Fc\u03b3R function in immune therapy: a pathway to next-gen mAbs","volume":"98","author":"Chenoweth","year":"2020","journal-title":"Immunol Cell Biol"},{"key":"2025111403144648100_bib12","doi-asserted-by":"crossref","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2023","journal-title":"Front Immunol"},{"key":"2025111403144648100_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-Positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025111403144648100_bib14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.2007.14.8957","article-title":"Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2\/neu-positive metastatic breast cancer","volume":"26","author":"Musolino","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025111403144648100_bib15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41467-018-03283-z","article-title":"Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer","volume":"9","author":"Patel","year":"2018","journal-title":"Nat Commun"},{"key":"2025111403144648100_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"2025111403144648100_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/0008-5472.CAN-22-2682","article-title":"Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer","volume":"83","author":"Bassiouni","year":"2023","journal-title":"Cancer Res"},{"key":"2025111403144648100_bib18","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1038\/srep05885","article-title":"A tool kit for rapid cloning and expression of recombinant antibodies","volume":"4","author":"Dodev","year":"2014","journal-title":"Sci Rep"},{"key":"2025111403144648100_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fimmu.2017.01112","article-title":"Functionally active Fc mutant antibodies recognizing cancer antigens generated rapidly at high yields","volume":"8","author":"Ilieva","year":"2017","journal-title":"Front Immunol"},{"key":"2025111403144648100_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/bit.21598","article-title":"Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function","volume":"99","author":"Zhou","year":"2008","journal-title":"Biotechnol Bioeng"},{"key":"2025111403144648100_bib21","doi-asserted-by":"crossref","first-page":"13455","DOI":"10.3390\/ijms232113455","article-title":"Generation and characterization of native and sialic acid-deficient IgE","volume":"23","author":"McCraw","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025111403144648100_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jim.2007.04.009","article-title":"Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis","volume":"323","author":"Bracher","year":"2007","journal-title":"J Immunol Methods"},{"key":"2025111403144648100_bib23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat Genet"},{"key":"2025111403144648100_bib24","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-15-2021","article-title":"Immune signatures following single dose trastuzumab predict pathologic response to preoperativetrastuzumab and chemotherapy in HER2-positive early breast cancer","volume":"22","author":"Varadan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025111403144648100_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jnci\/djy076","article-title":"Tumor-infiltrating lymphocytes in patients receiving Trastuzumab\/pertuzumab-based chemotherapy: a TRYPHAENA substudy","volume":"111","author":"Ignatiadis","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025111403144648100_bib26","doi-asserted-by":"crossref","first-page":"e003171","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025111403144648100_bib27","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","article-title":"Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods","volume":"79","author":"Jim\u00e9nez-S\u00e1nchez","year":"2019","journal-title":"Cancer Res"},{"key":"2025111403144648100_bib28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"2025111403144648100_bib29","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"key":"2025111403144648100_bib30","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025111403144648100_bib31","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"2025111403144648100_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/cimm.1994.1268","article-title":"Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C","volume":"158","author":"Borrego","year":"1994","journal-title":"Cell Immunol"},{"key":"2025111403144648100_bib33","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J Cell Biol"},{"key":"2025111403144648100_bib34","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"2025111403144648100_bib35","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-09-3704","article-title":"Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer","volume":"70","author":"Junttila","year":"2010","journal-title":"Cancer Res"},{"key":"2025111403144648100_bib36","doi-asserted-by":"crossref","first-page":"818736","DOI":"10.3389\/fimmu.2022.818736","article-title":"Sialylation as an important regulator of antibody function","volume":"13","author":"Vattepu","year":"2022","journal-title":"Front Immunol"},{"key":"2025111403144648100_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"2025111403144648100_bib38","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/jitc-2019-000491","article-title":"Lung metastases share common immune features regardless of primary tumor origin","volume":"8","author":"Garc\u00eda-Mulero","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025111403144648100_bib39","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","article-title":"Breast cancer lung metastasis: molecular biology and therapeutic implications","volume":"19","author":"Jin","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"2025111403144648100_bib40","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/0008-5472.CAN-21-0101","article-title":"Characterizing macrophage diversity in metastasis-bearing lungs reveals a lipid-associated macrophage subset","volume":"81","author":"Huggins","year":"2021","journal-title":"Cancer Res"},{"key":"2025111403144648100_bib41","doi-asserted-by":"crossref","first-page":"108374","DOI":"10.1016\/j.intimp.2021.108374","article-title":"Crosstalk between macrophages and natural killer cells in the tumor microenvironment","volume":"101","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2025111403144648100_bib42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1189\/jlb.0611308","article-title":"Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1","volume":"91","author":"Wang","year":"2012","journal-title":"J Leukoc Biol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-3174\/3660612\/can-24-3174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/22\/4521\/3667907\/can-24-3174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/22\/4521\/3667907\/can-24-3174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T08:14:57Z","timestamp":1763108097000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/22\/4521\/767086\/An-Fc-Engineered-Glycomodified-Antibody-Supports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":42,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2025,11,14]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-3174","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.30617695","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617710","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617701","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617713","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617704","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617707","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617689","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617698","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30617686","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8147728","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}